Log in

LTGO Latigo Biotherapeutics, Inc. NASDAQ · United States

Latigo Biotherapeutics (LTGO) news LTGO going concern, IPO and offering news

Latest Latigo Biotherapeutics news

  1. Financings

    Latigo Biotherapeutics files for IPO, plans Nasdaq listing as LTGO

    Latigo Biotherapeutics, Inc. filed a Form S-1 on July 17, 2026. The filing leaves the share count and price range blank, and the auditors have raised going-concern doubt.

Questions about Latigo Biotherapeutics

Has Latigo Biotherapeutics issued a going-concern warning?

Our latest story on this, dated Aug 7, 2026: "Latigo Biotherapeutics prices IPO of 19,200,000 shares at $18.00". The story links the filing or release it is based on. Read the story.

When did Latigo Biotherapeutics go public?

Our latest story on this, dated Aug 7, 2026: "Latigo Biotherapeutics prices IPO of 19,200,000 shares at $18.00". The story links the filing or release it is based on. Read the story.

Has Latigo Biotherapeutics raised money recently?

Our latest story on this, dated Aug 7, 2026: "Latigo Biotherapeutics prices IPO of 19,200,000 shares at $18.00". The story links the filing or release it is based on. Read the story.

What is the ticker symbol of Latigo Biotherapeutics?

Latigo Biotherapeutics, Inc. trades under the ticker LTGO on NASDAQ.

Where is Latigo Biotherapeutics listed?

Latigo Biotherapeutics, Inc. is listed on NASDAQ.

What is the SEC CIK of Latigo Biotherapeutics?

The SEC Central Index Key (CIK) for Latigo Biotherapeutics, Inc. is 2056611. Its filings are on SEC EDGAR.

How many shares does Latigo Biotherapeutics have outstanding?

66,299,347 shares as of 2026-09-01, per the cover page of its 10-Q filed 2026-09-03.

Which country or territory is Latigo Biotherapeutics listed under?

Our directory records Latigo Biotherapeutics, Inc. under United States.

What does Latigo Biotherapeutics do?

Our directory classifies Latigo Biotherapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Latigo Biotherapeutics?

The ISIN recorded for Latigo Biotherapeutics, Inc. is US5179541033.

Does aibio.space cover Latigo Biotherapeutics?

aibio.space lists Latigo Biotherapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is Latigo Biotherapeutics incorporated?

SEC records list its state or country of incorporation as DE.

What is the latest Latigo Biotherapeutics (LTGO) stock news?

Our latest story on Latigo Biotherapeutics, dated Aug 7, 2026: "Latigo Biotherapeutics prices IPO of 19,200,000 shares at $18.00". The offering totals $345,600,000 before underwriting discounts, and the company's auditors have raised going-concern doubt. Source.

How long will Latigo Biotherapeutics's cash last?

From our story of Aug 7, 2026: The offering totals $345,600,000 before underwriting discounts, and the company's auditors have raised going-concern doubt. Source.

Is Latigo Biotherapeutics a smaller reporting company?

SEC records list Latigo Biotherapeutics, Inc.'s filer category as: Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company.

Investor discussion: Latigo Biotherapeutics

Members talk about Latigo Biotherapeutics (LTGO). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Latigo Biotherapeutics, newest first. Each line links the filing it comes from.

  1. Distress

    Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source

  2. Financings

    Reported a financing. SEC Form 424B4. Source

  3. Financings

    Filed a registration statement for a share offering. SEC Form S-1. Source

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:LTGO on TradingView.

SEC filings and registration

SEC name
Latigo Biotherapeutics, Inc.
CIK
2056611
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
LTGO (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
December 31
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Business address
1300 RANCHO CONEJO BLVD., SUITE 305, THOUSAND OAKS, CA
Phone
805-716-2927
Shares outstanding
66,299,347 as of 2026-09-01 (10-Q filed 2026-09-03)

Recent filings (8-K and 6-K are the company's own announcements)

  • 10-Q filed 2026-09-03
  • 8-K filed 2026-09-03
  • 8-K filed 2026-08-10
  • S-1 filed 2026-07-17

Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

Listing details

Latigo Biotherapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker LTGO, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Latigo Biotherapeutics, Inc.
Ticker
LTGO
Listing
NASDAQ
Country or territory
United States
Business scope
Pharmaceuticals: Major
ISIN
US5179541033
Last quote in directory
2026-10-21
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.